In an ongoing pilot phase I study, the safety and efficacy of NKG2D CAR‐T cell therapy are being evaluated in patients with relapsed and/or refractory glioblastoma, and the outcome is expected to be released by 2023 (NCT04717999). Here, KLRK1 is linked to glioblastoma.